.png){kind=icon}
.png){kind=icon}
Return
Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial
.png){kind=icon}
OA
AI
S
R
D
B
C
DOI：10.1111/dom.70146.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Women with a history of gestational diabetes (GDM) frequently have progressive beta-cell dysfunction, which may result in type 2 diabetes. However, there is a paucity of clinical studies on strategies aiming to preserve beta-cell function in this patient population. This trial evaluated whether empagliflozin can preserve beta-cell function and reduce the prevalence of dysglycemia (prediabetes/diabetes) in women with recent GDM.
Keywords:
beta-cell function
gestational diabetes
pre-diabetes
SGLT-2 inhibitor
type 2 diabetes
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
D
IF:
5.7
Papers:
6.1K
Citations:
1.7W
Organization
Cited Papers